Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Cyclophosphamide 52Cytarabine 49fludarabine phosphate 38fludarabine 32Filgrastim 30Etoposide 23Rituximab 19Azacitidine 17Whole-Body Irradiation 16Tacrolimus 14Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Decitabine 13Clofarabine 13venetoclax 12Melphalan 12Antilymphocyte Serum 12Mycophenolic Acid 11Methotrexate 11Radiotherapy 10Mitoxantrone 10Daunorubicin 10Busulfan 10sargramostim 9aldesleukin 9Vincristine 9Sirolimus 9Topotecan 8Idarubicin 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia × ALT-801 × Clear all
NCT01478074 2014-01-03

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Altor BioScience

Phase 1 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡